Editorial Commentary: Barrier to Resistance: Lessons From 2 Direct-Acting Hepatitis C Virus Inhibitors, MK-5172 and Sofosbuvir.

/pubmed/25266288

Tong X, Kwong AD.

Clin Infect Dis. 2014 Dec 15;59(12):1675-7. doi: 10.1093/cid/ciu700. Epub 2014 Sep 28. No abstract available.

Clin Infect Dis. 2014

create date:2014/10/01 | first author:Tong X

Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

/pubmed/25266287

Svarovskaia ES, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, Martin R, Ouyang W, Han B, Xu S, Ku K, Chiu S, Gane E, Jacobson IM, Nelson DR, Lawitz E, Wyles DL, Bekele N, Brainard D, Symonds WT, McHutchison JG, Miller MD, Mo H.

Clin Infect Dis. 2014 Dec 15;59(12):1666-74. doi: 10.1093/cid/ciu697. Epub 2014 Sep 28.

Clin Infect Dis. 2014

create date:2014/10/01 | first author:Svarovskaia ES

Hepatitis C genotype 1.

/pubmed/25304394

Foster GR, De Silva S.

Curr Opin Infect Dis. 2014 Dec;27(6):535-9. doi: 10.1097/QCO.0000000000000112.

Curr Opin Infect Dis. 2014

create date:2014/10/12 | first author:Foster GR

Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment.

/pubmed/25028605

Gentile I, Borgia G.

Evid Based Med. 2014 Dec;19(6):223-4. doi: 10.1136/ebmed-2014-110051. Epub 2014 Jul 15. No abstract available.

Evid Based Med. 2014

create date:2014/07/17 | first author:Gentile I

Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus.

/pubmed/25175944

Summers BB, Beavers JW, Klibanov OM.

J Pharm Pharmacol. 2014 Dec;66(12):1653-66. doi: 10.1111/jphp.12294. Epub 2014 Aug 31.

J Pharm Pharmacol. 2014

create date:2014/09/02 | first author:Summers BB

Decompensated hepatitis C virus-related cirrhosis delisted from liver transplantation after successful sofosbuvir-based treatment.

/pubmed/25420476

Ruiz I, Feray C, Pawlotsky JM, Hezode C.

Liver Transpl. 2014 Nov 25. doi: 10.1002/lt.24051. [Epub ahead of print] No abstract available.

Liver Transpl. 2014

create date:2014/11/26 | first author:Ruiz I

How Safe Are Recently FDA-Approved Antimicrobials? A Review of the FDA Adverse Event Reporting System Database.

/pubmed/25421400

Khadem TM, van Manen RP, Brown J.

Pharmacotherapy. 2014 Nov 25. doi: 10.1002/phar.1519. [Epub ahead of print]

Pharmacotherapy. 2014

create date:2014/11/26 | first author:Khadem TM

Review: Telaprevir, boceprevir, simeprevir, or sofosbuvir improves response in HCV type 1.

/pubmed/25402532

Ann Intern Med. 2014 Nov 18;161(10):JC11. doi: 10.7326/0003-4819-161-10-201411180-02011. No abstract available.

Ann Intern Med. 2014

create date:2014/11/18 | first author:Koretz RL

Which therapeutic option for hepatitis C virus genotype 1?

/pubmed/25396710

Brochot E, Helle F, François C, Castelain S, Capron D, Nguyen-Khac E, Duverlie G.

Scand J Gastroenterol. 2014 Nov 14:1-9. [Epub ahead of print]

Scand J Gastroenterol. 2014

create date:2014/11/15 | first author:Brochot E

A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.

/pubmed/25372848

[No authors listed]

Med Lett Drugs Ther. 2014 Nov 10;56(1455):111-2. No abstract available.

Med Lett Drugs Ther. 2014

create date:2014/11/06

Hepatic Decompensation Likely Attributable to Simeprevir in Patients with Advanced Cirrhosis.

/pubmed/25373453

Stine JG, Intagliata N, Shah NL, Argo CK, Caldwell SH, Lewis JH, Northup PG.

Dig Dis Sci. 2014 Nov 6. [Epub ahead of print]

Dig Dis Sci. 2014

create date:2014/11/07 | first author:Stine JG

Optimal therapy in HCV liver transplant patients with direct acting antivirals.

/pubmed/25377540

Coilly A, Roche B, Duclos-Vallée JC, Samuel D.

Liver Int. 2014 Nov 6. doi: 10.1111/liv.12728. [Epub ahead of print]

create date:2014/11/08 | first author:Coilly A

Re-treatment of Chronic Hepatitis C Virus Genotype 1 Infection After Relapse: An Open-Label Pilot Study.

/pubmed/25364884

Osinusi A, Kohli A, Marti MM, Nelson A, Zhang X, Meissner EG, Silk R, Townsend K, Pang PS, Subramanian GM, McHutchison JG, Fauci AS, Masur H, Kottilil S.

Ann Intern Med. 2014 Nov 4;161(9):634-8. doi: 10.7326/M14-1211.

Ann Intern Med. 2014

create date:2014/11/05 | first author:Osinusi A

Editorial: patients' preferences and health utility assessment in those with HCV treated with sofosbuvir - stating the obvious? Authors' reply.

/pubmed/25280257

Stepanova M, Younossi Z.

Aliment Pharmacol Ther. 2014 Nov;40(9):1116. doi: 10.1111/apt.12955. No abstract available.

Aliment Pharmacol Ther. 2014

create date:2014/10/04 | first author:Stepanova M

Editorial: patients' preferences and health utility assessment in those with HCV treated with sofosbuvir - stating the obvious?

/pubmed/25280256

Lim SG, Gandhi M, Chan E.

Aliment Pharmacol Ther. 2014 Nov;40(9):1115. doi: 10.1111/apt.12945. No abstract available.

Aliment Pharmacol Ther. 2014

create date:2014/10/04 | first author:Lim SG

Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-Uninfected female subjects.

/pubmed/24925712

German P, Moorehead L, Pang P, Vimal M, Mathias A.

J Clin Pharmacol. 2014 Nov;54(11):1290-8. doi: 10.1002/jcph.346. Epub 2014 Jun 24.

J Clin Pharmacol. 2014

create date:2014/06/14 | first author:German P

Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.

/pubmed/25196837

Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, Toyoda H, Yokosuka O, Nirei K, Genda T, Umemura T, Takehara T, Sakamoto N, Nishigaki Y, Nakane K, Toda N, Ide T, Yanase M, Hino K, Gao B, Garrison KL, Dvory-Sobol H, et al.

J Viral Hepat. 2014 Nov;21(11):762-8. doi: 10.1111/jvh.12312. Epub 2014 Sep 8.

J Viral Hepat. 2014

create date:2014/09/10 | first author:Omata M

Sofosbuvir modulates the intimate relationship between hepatitis C virus and lipids.

/pubmed/25345724

Romero-Gómez M, Rojas A.

Hepatology. 2014 Oct 25. doi: 10.1002/hep.27581. [Epub ahead of print] No abstract available.

Hepatology. 2014

create date:2014/10/28 | first author:Romero-Gómez M

Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in u.s. Incarcerated populations: a cost-effectiveness analysis.

/pubmed/25329202

Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD.

Ann Intern Med. 2014 Oct 21;161(8):546-53. doi: 10.7326/M14-0602.

Ann Intern Med. 2014

create date:2014/10/21 | first author:Liu S

Sofosbuvir, Simeprevir plus Ribavirin for Treatment of HCV Recurrence in HIV-HCV Coinfected Liver Transplant Recipients.

/pubmed/25332190

Campos-Varela I, Straley S, Agudelo EZ, Carlson L, Terrault NA.

Liver Transpl. 2014 Oct 20. doi: 10.1002/lt.24027. [Epub ahead of print] No abstract available.

Liver Transpl. 2014

create date:2014/10/22 | first author:Campos-Varela I

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.

/pubmed/25322962

Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Dvory-Sobol H, Symonds WT, McHutchison JG, Membreno FE.

Hepatology. 2014 Oct 16. doi: 10.1002/hep.27567. [Epub ahead of print]

Hepatology. 2014

create date:2014/10/18 | first author:Lawitz E

Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.

/pubmed/25314116

Yoshida EM, Sulkowski MS, Gane EJ, Herring RW Jr, Ratziu V, Ding X, Wang J, Chuang SM, Ma J, McNally J, Stamm LM, Brainard DM, Symonds WT, McHutchison JG, Beavers KL, Jacobson IM, Reddy KR, Lawitz E.

Hepatology. 2014 Oct 14. doi: 10.1002/hep.27366. [Epub ahead of print]

Hepatology. 2014

create date:2014/10/15 | first author:Yoshida EM

Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C.

/pubmed/25311032

San Miguel R, Gimeno-Ballester V, Blázquez A, Mar J.

Gut. 2014 Oct 13. doi:pii: gutjnl-2014-307772. 10.1136/gutjnl-2014-307772. [Epub ahead of print]

create date:2014/10/15 | first author:San Miguel R

Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation.

/pubmed/25304641

Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, Fontana RJ, Gilroy R, Teperman L, Muir AJ, McHutchison JG, Symonds WT, Brainard D, Kirby B, Dvory-Sobol H, Denning J, Arterburn S, Samuel D, Forns X, Terrault NA.

Gastroenterology. 2014 Oct 7. doi:pii: S0016-5085(14)01194-9. 10.1053/j.gastro.2014.10.001. [Epub ahead of print]

Gastroenterology. 2014

create date:2014/10/12 | first author:Charlton M

Sofosbuvir (Sovaldi): Sofosbuvir is Indicated for the Treatment of Chronic Hepatitis C Virus (CHC) Infection in Adult Patients With Compensated Liver Disease, Including Cirrhosis [Internet].

/pubmed/25411675

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Oct.

create date:2014/11/21

Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir.

/pubmed/25038237

Stine JG, Cornella S, Shah NL.

Ann Rheum Dis. 2014 Oct;73(10):e64. doi: 10.1136/annrheumdis-2014-206180. Epub 2014 Jul 18. No abstract available.

Ann Rheum Dis. 2014

create date:2014/07/20 | first author:Stine JG

Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.

/pubmed/24879295

Lim PJ, Gallay PA.

Curr Opin Virol. 2014 Oct;8C:30-37. doi: 10.1016/j.coviro.2014.04.012. Epub 2014 May 27. Review.

Curr Opin Virol. 2014

PMID:24879295 | PMCID:PMC4195798

create date:2014/06/01 | first author:Lim PJ

Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.

/pubmed/24997638

Pellicelli AM, Montalbano M, Lionetti R, Durand C, Ferenci P, D'Offizi G, Knop V, Telese A, Lenci I, Andreoli A, Zeuzem S, Angelico M.

Dig Liver Dis. 2014 Oct;46(10):923-7. doi: 10.1016/j.dld.2014.06.004. Epub 2014 Jul 3.

Dig Liver Dis. 2014

create date:2014/07/07 | first author:Pellicelli AM

Recent advances in the treatment of hepatitis C.

/pubmed/25336034

Dhingra A, Kapoor S, Alqahtani SA.

Discov Med. 2014 Oct;18(99):203-8.

Discov Med. 2014

create date:2014/10/23 | first author:Dhingra A

GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection.

/pubmed/25096404

Gentile I, Buonomo AR, Zappulo E, Coppola N, Borgia G.

Expert Rev Anti Infect Ther. 2014 Oct;12(10):1179-86. doi: 10.1586/14787210.2014.945432. Epub 2014 Aug 5.

Expert Rev Anti Infect Ther. 2014

create date:2014/08/07 | first author:Gentile I

Sofosbuvir: A novel treatment option for chronic hepatitis C infection.

/pubmed/25422576

Bhatia HK, Singh H, Grewal N, Natt NK.

J Pharmacol Pharmacother. 2014 Oct;5(4):278-284.

J Pharmacol Pharmacother. 2014

create date:2014/11/26 | first author:Bhatia HK

Treatment of hepatitis B and C in children.

/pubmed/25253190

El-Shabrawi M, Hassanin F.

Minerva Pediatr. 2014 Oct;66(5):473-89.

Minerva Pediatr. 2014

create date:2014/09/26 | first author:El-Shabrawi M

Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era.

/pubmed/25387551

Berden FA, Kievit W, Baak LC, Bakker CM, Beuers U, Boucher CA, Brouwer JT, Burger DM, van Erpecum KJ, van Hoek B, Hoepelman AI, Honkoop P, Kerbert-Dreteler MJ, de Knegt RJ, Koek GH, van Nieuwkerk CM, van Soest H, Tan AC, Vrolijk JM, Drenth JP.

Neth J Med. 2014 Oct;72(8):388-400.

Neth J Med. 2014

create date:2014/11/13 | first author:Berden FA

Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection after Liver Transplantation: An Open-Label Study.

/pubmed/25261839

Curry MP, Forns X, Chung RT, Terrault NA, Brown R Jr, Fenkel JM, Gordon F, O'Leary J, Kuo A, Schiano T, Everson G, Schiff E, Befeler A, Gane E, Saab S, McHutchison JG, Subramanian GM, Symonds WT, Denning J, McNair L, Arterburn S, Svarovskaia E, et al.

Gastroenterology. 2014 Sep 24. doi:pii: S0016-5085(14)01145-7. 10.1053/j.gastro.2014.09.023. [Epub ahead of print]

Gastroenterology. 2014

create date:2014/09/28 | first author:Curry MP

Network meta-analysis of direct-acting antivirals in combination with peginterferon-ribavirin for previously untreated patients with hepatitis C genotype 1 infection.

/pubmed/25239762

Druyts E, Lorenzi M, Toor K, Thorlund K, Mills EJ.

QJM. 2014 Sep 19. doi:pii: hcu202. [Epub ahead of print]

create date:2014/09/23 | first author:Druyts E

Synthesis of 3',4'-difluoro-3'-deoxyribonucleosides and its evaluation of the biological activities: Discovery of a novel type of anti-HCV agent 3',4'-difluorocordycepin.

/pubmed/25282652

Shimada H, Haraguchi K, Hotta K, Miyaike T, Kitagawa Y, Tanaka H, Kaneda R, Abe H, Shuto S, Mori K, Ueda Y, Kato N, Snoeck R, Andrei G, Balzarini J.

Bioorg Med Chem. 2014 Sep 17. doi:pii: S0968-0896(14)00611-7. 10.1016/j.bmc.2014.08.024. [Epub ahead of print]

Bioorg Med Chem. 2014

create date:2014/10/06 | first author:Shimada H

Guideline: New HCV drugs should go to sickest patients.

/pubmed/25226461

JAMA. 2014 Sep 17;312(11):1084-5. doi: 10.1001/jama.2014.11373. No abstract available.

create date:2014/09/17 | first author:Kuehn BM

Advances in Therapy for HIV/Hepatitis C Virus-Coinfected Patients in the Liver Transplant Setting.

/pubmed/25228702

Campos-Varela I, Peters MG, Terrault NA.

Clin Infect Dis. 2014 Sep 16. doi:pii: ciu731. [Epub ahead of print]

Clin Infect Dis. 2014

create date:2014/09/18 | first author:Campos-Varela I

Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C.

/pubmed/25219291

Leleu H, Blachier M, Rosa I.

J Viral Hepat. 2014 Sep 15. doi: 10.1111/jvh.12311. [Epub ahead of print]

J Viral Hepat. 2014

create date:2014/09/16 | first author:Leleu H

Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic HCV, genotype-1 infected patients.

/pubmed/25203718

Meissner EG, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, McHutchison J, Subramanian M, Sampson M, Naggie S, Patel K, Remaley AT, Masur H, Kottilil S.

Hepatology. 2014 Sep 9. doi: 10.1002/hep.27424. [Epub ahead of print]

Hepatology. 2014

create date:2014/09/10 | first author:Meissner EG

Recent advances and future directions in the management of hepatitis C infections.

/pubmed/25200121

Belousova V, Abd-Rabou AA, Mousa SA.

Pharmacol Ther. 2014 Sep 6. doi:pii: S0163-7258(14)00164-8. 10.1016/j.pharmthera.2014.09.002. [Epub ahead of print] Review.

Pharmacol Ther. 2014

create date:2014/09/10 | first author:Belousova V

Inhibition of viral RNA polymerases by nucleoside and nucleotide analogs: therapeutic applications against positive-strand RNA viruses beyond hepatitis C virus.

/pubmed/25194816

Deval J, Symons JA, Beigelman L.

Curr Opin Virol. 2014 Sep 3;9C:1-7. doi: 10.1016/j.coviro.2014.08.004. [Epub ahead of print] Review.

Curr Opin Virol. 2014

create date:2014/09/10 | first author:Deval J

[New hepatitis C treatments: pharmacological considerations and potential for drug interactions].

/pubmed/25276998

Chtioui H, Buclin T, Moradpour D.

Rev Med Suisse. 2014 Sep 3;10(440):1600-4, 1606. French.

Rev Med Suisse. 2014

create date:2014/10/04 | first author:Chtioui H

CON Sofosbuvir and Ribavirin Use in Wait-Listed Patients with Hepatitis C Should be Selective.

/pubmed/25183500

Price JC, Terrault NA.

Liver Int. 2014 Sep 2. doi: 10.1111/liv.12679. [Epub ahead of print]

create date:2014/09/04 | first author:Price JC

Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.

/pubmed/25065960

Saab S, Gordon SC, Park H, Sulkowski M, Ahmed A, Younossi Z.

Aliment Pharmacol Ther. 2014 Sep;40(6):657-75. doi: 10.1111/apt.12871. Epub 2014 Jul 28.

Aliment Pharmacol Ther. 2014

create date:2014/07/30 | first author:Saab S

Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens.

/pubmed/25040192

Stepanova M, Nader F, Cure S, Bourhis F, Hunt S, Younossi ZM.

Aliment Pharmacol Ther. 2014 Sep;40(6):676-85. doi: 10.1111/apt.12880. Epub 2014 Jul 15.

Aliment Pharmacol Ther. 2014

create date:2014/07/22 | first author:Stepanova M

Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.

/pubmed/25229466

Yau AH, Yoshida EM.

Can J Gastroenterol Hepatol. 2014 Sep;28(8):445-51.

Can J Gastroenterol Hepatol. 2014

PMID:25229466 | PMCID:PMC4210236

create date:2014/09/18 | first author:Yau AH

HIV-hepatitis C virus co-infection in the era of direct-acting antivirals.

/pubmed/24996617

Bichoupan K, Dieterich DT, Martel-Laferrière V.

Curr HIV/AIDS Rep. 2014 Sep;11(3):241-9. doi: 10.1007/s11904-014-0217-9.

Curr HIV/AIDS Rep. 2014

create date:2014/07/06 | first author:Bichoupan K

Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus.

/pubmed/24848437

Gentile I, Coppola N, Buonomo AR, Zappulo E, Borgia G.

Expert Opin Investig Drugs. 2014 Sep;23(9):1211-23. doi: 10.1517/13543784.2014.921680. Epub 2014 May 21.

Expert Opin Investig Drugs. 2014

create date:2014/05/23 | first author:Gentile I

Sofosbuvir (Sovaldi) for the treatment of hepatitis C.

/pubmed/24918162

Lam B, Henry L, Younossi Z.

Expert Rev Clin Pharmacol. 2014 Sep;7(5):555-66. doi: 10.1586/17512433.2014.928196. Epub 2014 Jun 11.

Expert Rev Clin Pharmacol. 2014

create date:2014/06/12 | first author:Lam B

Daclatasvir for the treatment of hepatitis C virus infection.

/pubmed/24882552

Adler H, Lambert JS.

Expert Rev Gastroenterol Hepatol. 2014 Sep;8(7):725-38. doi: 10.1586/17474124.2014.925798. Epub 2014 May 31.

Expert Rev Gastroenterol Hepatol. 2014

create date:2014/06/03 | first author:Adler H

Emerging therapies for hepatitis C.

/pubmed/25228970

Kim do Y, Ahn SH, Han KH.

Gut Liver. 2014 Sep;8(5):471-9. doi: 10.5009/gnl14083. Epub 2014 Aug 18.

PMID:25228970 | PMCID:PMC4164256

create date:2014/09/18 | first author:Kim do Y

Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C.

/pubmed/25043847

Tsochatzis EA, Crossan C, Longworth L, Gurusamy K, Rodriguez-Peralvarez M, Mantzoukis K, O'Brien J, Thalassinos E, Papastergiou V, Noel-Storr A, Davidson B, Burroughs AK.

Hepatology. 2014 Sep;60(3):832-43. doi: 10.1002/hep.27296. Epub 2014 Jul 29. Review.

Hepatology. 2014

create date:2014/07/22 | first author:Tsochatzis EA

Sovaldi dilemma likely to get worse.

/pubmed/25282860

Manag Care. 2014 Sep;23(9):9, 12. No abstract available.

Manag Care. 2014

create date:2014/10/07 | first author:Carroll J

Antiviral medications for the treatment of hepatitis B and C infection and their effects on kidney function.

/pubmed/25027705

Murakami C, Melda Urekli H, Atta MG.

Minerva Gastroenterol Dietol. 2014 Sep;60(3):177-89. Epub 2014 Jul 16.

Minerva Gastroenterol Dietol. 2014

create date:2014/07/17 | first author:Murakami C

The solid-gold wonder drug. A long, difficult and costly research effort gives doctors a new cure for hepatitis C.

/pubmed/25211898

Sci Am. 2014 Sep;311(3):32, 34. No abstract available.

create date:2014/09/13 | first author:Wapner J

Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation.

/pubmed/25159822

Delabaudière C, Lavayssière L, Dörr G, Muscari F, Danjoux M, Sallusto F, Peron JM, Bureau C, Rostaing L, Izopet J, Kamar N.

Transpl Int. 2014 Aug 27. doi: 10.1111/tri.12428. [Epub ahead of print]

Transpl Int. 2014

create date:2014/08/28 | first author:Delabaudière C

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.

/pubmed/25123381

Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK.

Hepatology. 2014 Aug 14. doi: 10.1002/hep.27375. [Epub ahead of print]

Hepatology. 2014

create date:2014/08/16 | first author:Donaldson EF

Treatment of hepatitis C: a systematic review.

/pubmed/25117132

Kohli A, Shaffer A, Sherman A, Kottilil S.

JAMA. 2014 Aug 13;312(6):631-40. doi: 10.1001/jama.2014.7085. Review.

create date:2014/08/15 | first author:Kohli A

New expensive treatments for hepatitis C infection.

/pubmed/25038617

Brennan T, Shrank W.

JAMA. 2014 Aug 13;312(6):593-4. doi: 10.1001/jama.2014.8897. No abstract available.

create date:2014/07/21 | first author:Brennan T

Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.

/pubmed/25105742

Applegate TL, Gaudieri S, Plauzolles A, Chopra A, Grebely J, Lucas M, Hellard M, Luciani F, Dore GJ, Matthews GV.

Antivir Ther. 2014 Aug 8. doi: 10.3851/IMP2821. [Epub ahead of print]

Antivir Ther. 2014

create date:2014/08/12 | first author:Applegate TL

Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C after liver transplantation in HIV-HCV coinfected patient.

/pubmed/25105441

Borentain P, Colson P, Dhiver C, Gregoire E, Hardwigsen J; Danielle Botta-fridlund, Garcia S, Gerolami R.

Antivir Ther. 2014 Aug 8. doi: 10.3851/IMP2841. [Epub ahead of print]

Antivir Ther. 2014

create date:2014/08/12 | first author:Borentain P

Characterization of hepatitis C virus inter-genotypic recombinant strains and associated virologic response to sofosbuvir/ribavirin.

/pubmed/25099344

Hedskog C, Doehle B, Chodavarapu K, Gontcharova V, Crespo Garcia J, De Knegt R, Drenth JP, McHutchison JG, Brainard D, Stamm LM, Miller MD, Svarovskaia E, Mo H.

Hepatology. 2014 Aug 7. doi: 10.1002/hep.27361. [Epub ahead of print]

Hepatology. 2014

create date:2014/08/08 | first author:Hedskog C

Letter: calcineurin inhibitor level reduction during treatment with sofosbuvir in liver transplanted patients.

/pubmed/25040927

Vukotic R, Morelli MC, Pinna AD, Margotti M, Foschi FG, Loggi E, Bernardi M, Andreone P.

Aliment Pharmacol Ther. 2014 Aug;40(4):405. doi: 10.1111/apt.12853. No abstract available.

Aliment Pharmacol Ther. 2014

create date:2014/07/22 | first author:Vukotic R

Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides.

/pubmed/24867984

Furihata T, Matsumoto S, Fu Z, Tsubota A, Sun Y, Matsumoto S, Kobayashi K, Chiba K.

Antimicrob Agents Chemother. 2014 Aug;58(8):4555-64. doi: 10.1128/AAC.02724-14. Epub 2014 May 27.

Antimicrob Agents Chemother. 2014

PMID:24867984 | PMCID:PMC4135986

create date:2014/05/29 | first author:Furihata T

Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.

/pubmed/24316172

Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, Nelson D, Gerber L, Nader F, Hunt S.

Clin Gastroenterol Hepatol. 2014 Aug;12(8):1349-59.e13. doi: 10.1016/j.cgh.2013.11.032. Epub 2013 Dec 6.

Clin Gastroenterol Hepatol. 2014

create date:2013/12/10 | first author:Younossi ZM

Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.

/pubmed/24748524

Abraham GM, Spooner LM.

Clin Infect Dis. 2014 Aug;59(3):411-5. doi: 10.1093/cid/ciu265. Epub 2014 Apr 18.

Clin Infect Dis. 2014

create date:2014/04/22 | first author:Abraham GM

The current state and future prospects of chronic hepatitis C virus infection treatment.

/pubmed/24893980

Moore C, Levitsky J.

Curr Infect Dis Rep. 2014 Aug;16(8):413. doi: 10.1007/s11908-014-0413-1.

Curr Infect Dis Rep. 2014

create date:2014/06/05 | first author:Moore C

Advances in and the future of treatments for hepatitis C.

/pubmed/24846594

Cheng R, Tu T, Shackel N, McCaughan GW.

Expert Rev Gastroenterol Hepatol. 2014 Aug;8(6):633-47. doi: 10.1586/17474124.2014.909725. Epub 2014 May 20.

Expert Rev Gastroenterol Hepatol. 2014

create date:2014/05/23 | first author:Cheng R

Combination of daclatasvir and sofosbuvir for hepatitis C genotypes 1, 2, and 3.

/pubmed/24953626

Gastroenterology. 2014 Aug;147(2):534-6. doi: 10.1053/j.gastro.2014.06.016. Epub 2014 Jun 20. No abstract available.

Gastroenterology. 2014

create date:2014/06/24 | first author:Bari K

Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients.

/pubmed/25034873

Liu X, Wang Y, Zhang G, Li N, Zhu Q, Chang H, Han Q, Lv Y, Liu Z.

Int J Antimicrob Agents. 2014 Aug;44(2):145-51. doi: 10.1016/j.ijantimicag.2014.04.018. Epub 2014 Jun 10.

Int J Antimicrob Agents. 2014

create date:2014/07/19 | first author:Liu X

Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.

/pubmed/24983321

Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, Porcella S, Wang H, Herrmann E, McHutchison J, Suffredini AF, Polis M, Hewitt S, Prokunina-Olsson L, Masur H, Fauci AS, Kottilil S.

J Clin Invest. 2014 Aug 1;124(8):3352-63. doi: 10.1172/JCI75938. Epub 2014 Jul 1.

J Clin Invest. 2014

PMID:24983321 | PMCID:PMC4109554

create date:2014/07/02 | first author:Meissner EG

Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy.

/pubmed/24816173

J Hepatol. 2014 Aug;61(2):435-8. doi: 10.1016/j.jhep.2014.04.042. Epub 2014 May 6. No abstract available.

create date:2014/05/13 | first author:Asselah T

Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.

/pubmed/24713186

Younossi ZM, Stepanova M, Zeuzem S, Dusheiko G, Esteban R, Hezode C, Reesink HW, Weiland O, Nader F, Hunt SL.

J Hepatol. 2014 Aug;61(2):228-34. doi: 10.1016/j.jhep.2014.04.003. Epub 2014 Apr 5.

create date:2014/04/10 | first author:Younossi ZM

Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?

/pubmed/25074044

Donato MF, Monico S, Malinverno F, Aghemo A, Maggioni M, Reggiani P, Colombo M.

Liver Int. 2014 Jul 29. doi: 10.1111/liv.12646. [Epub ahead of print]

create date:2014/07/31 | first author:Donato MF

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

/pubmed/25078309

Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM.

Lancet. 2014 Jul 26. doi:pii: S0140-6736(14)61036-9. 10.1016/S0140-6736(14)61036-9. [Epub ahead of print]

create date:2014/08/01 | first author:Lawitz E

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

/pubmed/25038354

Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Rodriguez-Torres M, Dieterich D; PHOTON-1 Investigators.

JAMA. 2014 Jul 23-30;312(4):353-61. doi: 10.1001/jama.2014.7734. Erratum in: JAMA. 2014 Nov 12;312(18):1932.

create date:2014/07/20 | first author:Sulkowski MS

Quantum leaps, microeconomics, and the treatment of patients with hepatitis C and HIV coinfection.

/pubmed/25038351

JAMA. 2014 Jul 23-30;312(4):347-8. doi: 10.1001/jama.2014.7735. No abstract available.

create date:2014/07/20 | first author:Saag MS

Medicine. Hepatitis C can be cured globally, but at what cost?

/pubmed/25013048

Science. 2014 Jul 11;345(6193):141-2. doi: 10.1126/science.1257737. No abstract available.

create date:2014/07/12 | first author:Hill A

Antiviral treatment of hepatitis C.

/pubmed/25002352

Feeney ER, Chung RT.

BMJ. 2014 Jul 7;348:g3308. doi: 10.1136/bmj.g3308. Review.

create date:2014/07/09 | first author:Feeney ER

Sofosbuvir for the treatment of hepatitis C virus infection.

/pubmed/25002563

Rolland S, Vachon ML.

CMAJ. 2014 Jul 7. doi:pii: cmaj.140151. [Epub ahead of print] No abstract available.

create date:2014/07/09 | first author:Rolland S

Recent advances in rilpivirine: new data and promising treatment option.

/pubmed/25221991

Casado JL, Bañón S.

AIDS Rev. 2014 Jul-Sep;16(3):172-81.

create date:2014/09/16 | first author:Casado JL

Letter: estimating the cost-neutral price of sofosbuvir-based triple therapy for the treatment of naïve patients with genotype 1 HCV infection in Italy.

/pubmed/24946068

Messori A, Maratea D, Fadda V, Trippoli S.

Aliment Pharmacol Ther. 2014 Jul;40(2):217-8. doi: 10.1111/apt.12823. No abstract available.

Aliment Pharmacol Ther. 2014

create date:2014/06/20 | first author:Messori A

Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase.

/pubmed/24733478

Fung A, Jin Z, Dyatkina N, Wang G, Beigelman L, Deval J.

Antimicrob Agents Chemother. 2014 Jul;58(7):3636-45. doi: 10.1128/AAC.02666-14. Epub 2014 Apr 14.

Antimicrob Agents Chemother. 2014

PMID:24733478 | PMCID:PMC4068585

create date:2014/04/16 | first author:Fung A

Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?

/pubmed/24792751

Antiviral Res. 2014 Jul;107:119-24. doi: 10.1016/j.antiviral.2014.04.008. Epub 2014 May 2.

Antiviral Res. 2014

create date:2014/05/06 | first author:Sofia MJ

Sofosbuvir: a review of its use in patients with chronic hepatitis C.

/pubmed/24958336

Drugs. 2014 Jul;74(10):1127-46. doi: 10.1007/s40265-014-0247-z.

create date:2014/06/25 | first author:Keating GM

An Italian perspective: studying the cost-effectiveness of sofosbuvir before completion of national price negotiations.

/pubmed/24901827

Messori A, Maratea D, Fadda V, Gatto R, Trippoli S.

Eur J Gastroenterol Hepatol. 2014 Jul;26(7):813-4. doi: 10.1097/MEG.0000000000000107. No abstract available.

Eur J Gastroenterol Hepatol. 2014

create date:2014/06/06 | first author:Messori A

Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?

/pubmed/24918116

Gentile I, Buonomo AR, Zappulo E, Borgia G.

Expert Rev Anti Infect Ther. 2014 Jul;12(7):763-73. doi: 10.1586/14787210.2014.929497.

Expert Rev Anti Infect Ther. 2014

create date:2014/06/12 | first author:Gentile I

[Chronic hepatitis C infection--eradication of the virus].

/pubmed/25189028

Harefuah. 2014 Jul;153(7):392-3, 433. Hebrew.

create date:2014/09/06 | first author:Ben Ari Z

Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.

/pubmed/24825115

Pho MT, Linas BP.

Hepatology. 2014 Jul;60(1):12-4. doi: 10.1002/hep.27220. No abstract available.

Hepatology. 2014

PMID:24825115 | PMCID:PMC4096113

create date:2014/05/16 | first author:Pho MT

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.

/pubmed/24677184

Hagan LM, Sulkowski MS, Schinazi RF.

Hepatology. 2014 Jul;60(1):37-45. doi: 10.1002/hep.27151. Epub 2014 May 14.

Hepatology. 2014

PMID:24677184 | PMCID:PMC4077973

create date:2014/03/29 | first author:Hagan LM

All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection.

/pubmed/24501005

Wyles DL, Rodriguez-Torres M, Lawitz E, Shiffman ML, Pol S, Herring RW, Massetto B, Kanwar B, Trenkle JD, Pang PS, Zhu Y, Mo H, Brainard DM, Subramanian GM, McHutchison JG, Habersetzer F, Sulkowski MS.

Hepatology. 2014 Jul;60(1):56-64. doi: 10.1002/hep.27053. Epub 2014 May 28.

Hepatology. 2014

create date:2014/02/07 | first author:Wyles DL

The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection.

/pubmed/24798321

Ollendorf DA, Tice JA, Pearson SD.

JAMA Intern Med. 2014 Jul;174(7):1170-1. doi: 10.1001/jamainternmed.2014.2151. Review. No abstract available.

JAMA Intern Med. 2014

create date:2014/05/07 | first author:Ollendorf DA

The high price of the new hepatitis C virus drugs.

/pubmed/24798183

Steinbrook R, Redberg RF.

JAMA Intern Med. 2014 Jul;174(7):1172. doi: 10.1001/jamainternmed.2014.2135. No abstract available.

JAMA Intern Med. 2014

create date:2014/05/07 | first author:Steinbrook R

My treatment approach to chronic hepatitis C virus.

/pubmed/24867397

Shiffman ML, Long AG, James A, Alexander P.

Mayo Clin Proc. 2014 Jul;89(7):934-42. doi: 10.1016/j.mayocp.2014.04.013. Epub 2014 May 24.

Mayo Clin Proc. 2014

create date:2014/05/29 | first author:Shiffman ML

[Experience in the management of immunosuppressant treatment with hepatitis C virus protease inhibitors.]

/pubmed/24951300

Ruiz Ramos J, Romero Hernández I, Marrero Álvarez P, Marqués Miñana MR, Fernández Megía MJ, Poveda Andrés JL.

Gastroenterol Hepatol. 2014 Jun 18. doi:pii: S0210-5705(14)00148-4. 10.1016/j.gastrohep.2014.05.004. [Epub ahead of print] Spanish.

Gastroenterol Hepatol. 2014

create date:2014/06/22 | first author:Ruiz Ramos J

Current race in the development of DAAs (direct-acting antivirals) against HCV.

/pubmed/24735613

Biochem Pharmacol. 2014 Jun 15;89(4):441-52. doi: 10.1016/j.bcp.2014.04.005. Epub 2014 Apr 13.

Biochem Pharmacol. 2014

create date:2014/04/17 | first author:De Clercq E

[Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].

/pubmed/25026860

[No authors listed]

MMW Fortschr Med. 2014 Jun 12;156 Suppl 1:53. German. No abstract available.

MMW Fortschr Med. 2014

create date:2014/07/17

WHO issues guidelines on HCV amid drug cost controversy.

/pubmed/24915242

JAMA. 2014 Jun 11;311(22):2262-3. doi: 10.1001/jama.2014.5277. No abstract available.

create date:2014/06/11 | first author:Slomski A